Skip to main content

PERCEPTIVE ADVISORS LLC

Position in AMLX — Amylyx Pharmaceuticals, Inc.

CIK 1224962 NEW YORK, NY

Position in AMLX

as of Mar 31, 2026 · filed May 29, 2026
Position Value
$115,159,859
+$15,078,485 QoQ
Shares Held
8,284,882
0.0% QoQ
Ownership
7.45%
of shares outstanding
% of Portfolio
2.29%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2022
16 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in AMLX Over Time

Shares Held

Position Value (USD)

Derivatives in AMLX

reported options exposure · as of Mar 31, 2024
CallValue
$4,768,715
CallShares
1,679,125
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - Specialty & Generic

Healthcare · as of Mar 31, 2026

PERCEPTIVE ADVISORS LLC holds $200,430,720 across 5 Drug Manufacturers - Specialty & Generic names. AMLX ranks #1 (57.5% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 AMLX
Amylyx Pharmaceuticals, Inc.
This page
8,284,882 $115,159,859

All Filings in AMLX

Export CSV
18 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $115,159,859 8,284,882
2025-12-31 $100,081,374 8,284,882
2025-09-30 $121,662,640 8,952,365
2025-09-30 $121,662,640 8,952,365
2025-06-30 $50,654,159 7,902,365
2025-03-31 $27,875,191 7,874,348
2024-12-31 $25,607,035 6,774,348
2024-09-30 $6,887,102 2,125,649
2024-03-31 $852,000 300,000
2024-03-31 $4,768,715 1,679,125
2023-12-31 $27,513,520 1,869,125
2023-09-30 $49,233,264 2,688,873
2023-06-30 $105,130,432 4,873,919
2023-03-31 $177,056,454 6,034,644
2022-12-31 $224,963,904 6,088,333
2022-09-30 $154,037,728 5,472,033
2022-06-30 $68,188,258 3,540,408
2022-03-31 $18,942,274 1,474,107